ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO991

Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Kooienga, Laura, Colorado Kidney Care, Denver, Colorado, United States
  • Suzuki, Yusuke, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Chacko, Bobby, John Hunter Hospital, New Lambton Heights, New South Wales, Australia
  • Wong, Muh Geot, Royal North Shore Hospital, St Leonards, New South Wales, Australia
  • Barratt, Jonathan, University of Leicester, Leicester, Leicestershire, United Kingdom
  • Oh, Kook-Hwan, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Sahay, Manisha, Osmania Medical College, Hyderabad, Telangana, India
  • Mathur, Mohit, Visterra Inc., Boston, Massachusetts, United States
  • Wang, Xiaofeng, Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville, Maryland, United States
  • Yarbrough, Jill, Visterra Inc., Boston, Massachusetts, United States
  • Pereira, Brian J.G., Visterra Inc., Boston, Maryland, United States

Pathogenesis of primary Immunoglobulin A Nephropathy (IgAN) is driven by A Proliferation-Inducing Ligand (APRIL). Sibeprenlimab is a humanized IgG2 monoclonal antibody that prevents APRIL signaling.


VIS649-201 (NCT04287985) is a global multicenter, randomized controlled study evaluating monthly intravenous (IV) Sibeprenlimab (2, 4, or 8 mg/kg) versus placebo in adults with IgAN on optimized supportive treatment, who have eGFR ≥ 30 ml/min/1.73m2 and proteinuria ≥ 1.0 g/d or urine protein creatinine ratio (uPCR) ≥ 0.75 g/g. A protocol specified group unblinded IA was conducted when 72 participants completed month-9 of a 12-month study course.


Among pooled Sibeprenlimab recipients there was a 43% placebo-adjusted reduction from baseline in 24-hour uPCR values at month 9 (Figure 1a) with reduction in serum APRIL, total IgA & galactose-deficient IgA1. Among subjects with ≥ 9 months on study, the estimated annualized eGFR slope was stable (+1.2 mL/min/1.73m2/year) in pooled Sibeprenlimab recipients versus declining (-6.5 mL/min/1.73m2 /year) in the placebo group, with a slope difference of +7.7 mL/min/1.73m2/year (95% CI 1.32 to 14.01). The mean of eGFR change from baseline over time is shown in Figure 1b. No serious adverse events were considered study-drug related & most adverse events were mild or moderate in severity.


This Phase 2 IA of a precision therapeutic for IgAN, Sibeprenlimab, demonstrated acceptable safety & tolerability with robust uPCR reduction associated with eGFR stability, when compared to the placebo arm at 9 months of study follow up.


  • Commercial Support –